NCT04390672

Multivessel TALENT

A Randomized Controlled Trial to Compare the Safety and Efficacy of siroliMUs-eLuTIng Biodegradable Polymer ulTrA-thin Stent (SUPRAFLEX Cruz) and Everolimus-eLuting Biodegradable Polymer Stent (SYNERGY) in treatmENT for Three-vessel Coronary Artery Disease: Multivessel TALENT

• Status: Active Not Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 1,550 (estimated)
• Sponsor: National University of Ireland, Galway, Ireland · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Multivessel TALENT is a prospective, randomized, multi-center study comparing clinical outcomes between SUPRAFLEX Cruz and SYNERGY in approximately 1550 patients with de-novo three vessel disease undergoing percutaneous coronary intervention (PCI). Patients will be treated according to "state of art PCI"; not only treatment strategies based on the latest ESC guideline, such as SYNTAX Score II recommendation, Heart Team discussion, post-procedure intravascular imaging optimization, cholesterol reduction by statin or PCSK-9 inhibitor, but also exploratory treatment strategies based on the latest evidence, such as physiological assessment using quantitative flow ratio and prasugrel monotherapy following 1-month dual antiplatelet therapy after PCI.

Conditions

• Coronary Artery Disease
• Myocardial Ischemia
• Coronary Disease
• Heart Diseases
• Cardiovascular Diseases
• Arterial Occlusive Diseases
• Vascular Diseases

Interventions

Type	Name	Description
DEVICE	SUPRAFLEX Cruz	Percutaneous Coronary Intervention for multivessel disease
DEVICE	SYNERGY	Percutaneous Coronary Intervention for multivessel disease

Timeline

• Start date: 2020-09-22
• Primary completion: 2025-09-23
• Completion: 2026-09-01
• First posted: 2020-05-15
• Last updated: 2026-02-27

Locations

1 site across 1 country: Ireland